Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.
NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
Accurately classifying patients with psoriatic arthritis (PsA) can be difficult, especially patients with monoarticular/oligoarticular and polyarticular forms of PsA. A session at the 2019 European Congress of Rheumatology provided insight into the assessment and treatment of PsA subtypes…
Sir William Osler, widely regarded as one of the greatest physicians of the 20th century, once said, “He who studies medicine without books sails an uncharted sea, but he who studies medicine without patients does not go to sea at all.”1 This sentiment is particularly true in the field of rheumatology, in which understanding the…
It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondyloarthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…
(Reuters Health)—Behavior changes could potentially reduce a large part of the risk for developing gout, a U.S. study suggests. Based on data from more than 14,000 people, researchers calculated how much factors like being overweight, following a diet that isn’t heart healthy, drinking alcohol or taking diuretics contribute to high levels of uric acid—a precursor…
As the 21st century unfolds, rheumatologists will most likely transition from prescribing lupus patients broad immunosuppressants to more targeted treatment approaches. But to make this happen and advance research, the challenges experienced in lupus clinical trial design must be addressed…
The recently updated Osteoarthritis Research Society International (OARSI) guideline offers comprehensive and patient-centered treatment approaches for individuals with knee, hip and polyarticular OA…
A 32-year-old male patient with rheumatoid arthritis affecting multiple joints without rheumatoid factor returns to the office for a follow-up visit with the nurse practitioner (NP). The patient states his overall pain has improved since his previous visit, although he rates the severity of his right shoulder and right wrist pain at a 5 on…
An antibody previously un-recognized in patients with Sjögren’s syndrome may shed new light on the pathophysiology of one of the most troubling and disabling symptoms in many of these patients. Investigators at Johns Hopkins University, Baltimore, found the anti-calponin 3 antibody had a high specificity for Sjögren’s syndrome, particularly among patients with neuropathies.1 “There is…